Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Company Overview:
It is a biotech research and development company that is developing antibody drugs for cancer treatment.
The company specializes in the development of targeted oncology immunotherapies, with a particular focus on agonizing monoclonal and bispecific antibodies.
In immunotherapy, a patient's immune system is activated to cure cancer. The term "tumor-targeting" refers to the administration or design of a drug so that its pharmacological effects are confined to the tumor. This can ensure the efficacy and safety of the treatment.
The company is primarily active in the early stages of drug development, from conception through phase II clinical trials, which include identifying innovative modalities of action for drugs, producing and optimizing new drug candidates, evaluating preclinical efficacy and safety, and ultimately conducting confirmatory clinical studies in cancer patients.
Target strategy:
The company aims to establish long-term strategic and value creation partnerships with the pharmaceutical and biotechnology industries as well as academic institutions.
The strategy is to develop drug candidates into Phase II clinical trials, but the company plans to consider outsourcing licensing or co-development partnerships at an earlier stage.
The public-company partnership in a research or preclinical development project may be in the form of a license of non-material rights or in the form of a joint development of a drug candidate, where costs and future benefits are shared between the parties.
The company has signed an agreement with an American biotech company to jointly develop bispecific drug candidates. Under the terms of the agreement, the parties will jointly own and equally share the development costs associated with advancing the drug candidate through the end of Phase II clinical development.
Cooperation Intention:
The company is looking for opportunities to collaborate with biotech companies as well as academic institutions to jointly develop innovative immunotherapies.